Uppsala, 20 March 2023. OssDsign AB (publ.) announces today that the company has significantly reduced Cranial PSI lead times up to 40 percent through optimizations in the manufacturing process. By delivering on this important milestone, OssDsign enhances the offering and substantially improve the product’s competitiveness and growth potential.
In line with OssDsign’s strategy ASCENT25, the company delivers on the strategic priority of operational efficiency by significantly improving the OssDsign Cranial PSI manufacturing process. Moving forward, the reduction in lead times will allow for deliveries within three weeks for all OssDsign Cranial PSI orders and across all geographies – an important milestone that will increase relevance for more cases.
”Lead time optimization has been an important focus for OssDsign during the last 12 months and this major step will increase the competitiveness of OssDsign Cranial PSI. Whilst we will continue to work diligently on operational efficiency going forward, the new lead time will improve our ability to further accelerate growth, especially in the U.S.,” said Morten Henneveld, CEO, OssDsign.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient’s own bone. Over time, the calcium phosphate composition degrades and is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: firstname.lastname@example.org
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: email@example.com
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.